• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

INOVIO PHARMACEUTICALS, INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR Jacqueline E Shea PhD

2

DIRECTOR Simon X. Benito

3

DIRECTOR Roger D. Dansey, M.D.

4

DIRECTOR Ann C. Miller, M.D.

5

DIRECTOR Jay P. Shepard

6

DIRECTOR David B. Weiner, Ph.D.

7

DIRECTOR Wendy L. Yarno

8

DIRECTOR Lota S. Zoth

9

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

10

To approve, on a non-binding advisory basis, the resolution regarding compensation of our named executive officers described in the accompanying proxy statement.

11

To approve an amendment and restatement of our Amended and Restated 2023 Omnibus Incentive Plan.